GC Genome Enters African Market with Genetic Testing MOU

GC Genome (CEO Chang-Seok Ki) announced on September 12th its agreement with Egypt's Technobiomed to supply genetic diagnostic testing services, marking the company's first entry into the African market. This partnership sets the stage for GC Genome’s full-scale entry into Egypt.

With a population exceeding 100 million, Egypt is a strategic hub for North Africa, the Middle East, and the Arab world, offering significant market potential. Technobiomed, Egypt’s first healthcare company to offer early cervical cancer screening, operates clinical laboratories that provide a range of diagnostics, from general to molecular, cytogenetic, and pathology tests, contributing to the country’s public health sector.

As part of the agreement, Technobiomed will expand its genetic testing portfolio by launching GC Genome’s multi-cancer early detection test, ai-CANCERCH, in Egypt later this year. The focus will be on increasing test requests from Egypt’s upper class, particularly in the cancer screening market.

Following the contract, additional requests have been received for tests such as the non-invasive prenatal fetal chromosomal abnormality test (G-NIPT) and the hereditary female cancer panel test. Both companies expect to strengthen their collaboration and generate further synergy.

Chang-Seok Ki, CEO of GC Genome, remarked, “This contract marks our first success in Egypt, a key market in Africa. We are confident that our globally recognized genetic testing services will gain attention and serve as a stepping stone for expanding our business across the continent.”